[Immunomodulatory effects of intravenous immunoglobulins].
Intravenous immunoglobulin (IVIg) has been used for many years in the treatment of primary and secondary antibody deficiencies. IVIg was first demonstrated to be effective in auto-immune desorders twenty years ago in the treatment of idiopathic thrombocytopenic purpura. The beneficial effect of IVIg has since been established in the Guillain-Barré syndrome, chronic inflammatory demenilating polyneuropathy, myasthenia gravis, dermatomyositis, Kawasaki syndrome and graft versus host disease. The beneficial effect of IVIg has been suggested in a large number of other auto-immune and systemic inflammatory conditions. The mode of action of IVIg is complex, involving Fc receptor blockade, interference with complement activation and the cytokine network, provision of anti-idiotypic antibodies and modulation of T and B cell activation and differentiation. Such a broad range of activities reflects the function of normal circulating immunoglobulins in maintaining tolerance to self in healthy individuals.
Kazatchkine
M
M
Service d'Immunologie et INSERM U430, Hôpital Broussais et Université Pierre-et-Marie-Curie, Paris.
Mouthon
L
L
Kaveri
S V
SV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000628:therapy; D003167:Complement Activation / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D008213:Lymphocyte Activation / Q000276:immunology; D011115:Polyneuropathies / Q000628:therapy; D011961:Receptors, Fc / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D000888:Antibodies, Anti-Idiotypic; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D011961:Receptors, Fc